Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.43 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.43 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.43 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.43 |
| ▸ | PRCP | P42785 | 1/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.43 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7458612 | 0.85 | OPRM1 (0.34) | OPRM1 | |
| SCHEMBL8812050 | 0.83 | OPRM1 (0.36) | SLC6A2SLC6A4SLC6A3GRIN1GRIN2A | |
| SCHEMBL5971560 | 0.83 | SLC6A4 (0.35) | SLC6A2SLC6A4SLC6A3KCNH2OPRM1 | |
| SCHEMBL30580699 | 0.83 | HSD11B1 (0.37) | SLC6A2SLC6A4SLC6A3KCNH2OPRM1 | |
| SCHEMBL4781128 | 0.83 | HSD11B1 (0.34) | SLC6A4GRIN1GRIN2AGRIN2B | |
| SCHEMBL4669798 | 0.82 | OPRK1 (0.38) | SLC6A2SLC6A4SLC6A3OPRM1OPRD1 | |
| SCHEMBL7121073 | 0.78 | OPRL1 (0.35) | KCNH2GRIN2BOPRM1OPRD1OPRL1 | |
| SCHEMBL30189641 | 0.78 | KCNH2 (0.33) | SLC6A2SLC6A4SLC6A3KCNH2GRIN2B | |
| SCHEMBL4593876 | 0.76 | SLC6A4 (0.50) | SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL11096567 | 0.76 | OPRM1 (0.46) | KCNH2OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 374 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| EP-4106872-A1 | COMPOSITIONS AND METHODS FOR ASSESSING THE EFFICACY OF INHIBITORS OF NEUROTRANSMITTER TRANSPORTERS | Denovo Biopharma LLC (US) | 2022-12-28 | — | — | EP | claimed |
| CN-115515680-A | Compositions and methods for assessing efficacy of neurotransmitter transporter inhibitors | 索元生物医药有限公司 | 2022-12-23 | — | — | CN | claimed |
| EP-3558396-B1 | DIFFERENTIAL DIAGNOSIS OF PARKINSON'S DISEASE | GE HEALTHCARE LTD (GB) | 2021-11-24 | — | — | EP | claimed |
| US-10980899-B2 | Differential diagnosis | GE HEALTHCARE LIMITED (GB) | 2021-04-20 | — | — | US | claimed |
| US-20190328909-A1 | DIFFERENTIAL DIAGNOSIS | ACADEMIC MEDICAL CENTER (NL) | 2019-10-31 | — | — | US | claimed |
| EP-3558396-A1 | DIFFERENTIAL DIAGNOSIS OF PARKINSON'S DISEASE | GE Healthcare Limited (GB) | 2019-10-30 | — | — | EP | claimed |
| WO-2018115148-A1 | DIFFERENTIAL DIAGNOSIS OF PARKINSON'S DISEASE | GE HEALTHCARE LIMITED (GB) | 2018-06-28 | — | — | WO | claimed |
| WO-2012056452-A2 | PHARMACEUTICAL COMPOSITIONS AND DELIVERY DEVICES COMPRISING STINGING CELLS OR CAPSULES | NANOCYTE (ISRAEL) LTD. (IL) | 2012-05-03 | — | — | WO | claimed |
| EP-1590007-B1 | IMPROVED RADIOMETAL COMPLEX COMPOSITIONS | GE HEALTHCARE LTD (GB) | 2010-11-10 | — | — | EP | claimed |
| US-20030109708-A1 | Process for synthesizing anhydroecgonine derivative | NIHON MEDI-PHYSICS CO., LTD. | 2003-06-12 | — | — | US | claimed |
| WO-2003037313-A2 | METHODS FOR THE TREATMENT OF ADDICTION | RECOVERY PHARMACEUTICALS, INC. (US) | 2003-05-08 | — | — | WO | claimed |
| US-20020159949-A1 | Methods for diagnosing and monitoring treatment ADHD by assessing the dopamine transporter level | THE GENERAL HOSPITAL CORPORATION | 2002-10-31 | — | — | US | claimed |
| US-20020150535-A1 | Methods for diagnosing and monitoring treatment ADHD by assessing the dopamine transporter level | MADRAS BERTHA K (US) | 2002-10-17 | — | — | US | claimed |
| EP-1196083-A1 | IMAGING THE DOPAMINE TRANSPORTER TO DETERMINE AD-HD | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2002-04-17 | — | — | EP | claimed |
| WO-2001090716-A2 | LINKER ARMS FOR NANOCRYSTALS AND COMPOUNDS THEREOF | VANDERBILT UNIVERSITY (US) | 2001-11-29 | — | — | WO | claimed |
| WO-2001090717-A2 | LINKER ARMS FOR NANOCRYSTALS AND COMPOUNDS THEREOF | VANDERBILT UNIVERSITY (US) | 2001-11-29 | — | — | WO | claimed |
| US-20010020096-A1 | Process for synthesizing anhydroecgonine derivative | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2001-09-06 | — | — | US | claimed |
| EP-1127887-A1 | Process for synthesizing anhydroecgonine derivative | NIHON MEDI-PHYSICS Co., Ltd. (JP) | 2001-08-29 | — | — | EP | claimed |
| WO-2001000082-A1 | IMAGING THE DOPAMINE TRANSPORTER TO DETERMINE AD-HD | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2001-01-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10980899-B2 | Differential diagnosis | PARK7, SNCA, PSPH | SLC6A2 244/4885SLC6A4 833/4885SLC6A3 51/4885 |
| US-20190328909-A1 | DIFFERENTIAL DIAGNOSIS | PARK7, SNCA, PSPH | SLC6A2 244/4885SLC6A4 833/4885SLC6A3 51/4885 |
| US-20020150535-A1 | Methods for diagnosing and monitoring treatment ADHD by assessing the dopamine transporter level | SLC6A3, SLC6A2, SLC18A2 | SLC6A2 2/4885SLC6A4 4/4885SLC6A3 1/4885 |
| US-20030109708-A1 | Process for synthesizing anhydroecgonine derivative | CES2, NPR1, OPRL1 | SLC6A2 185/4885SLC6A4 908/4885SLC6A3 385/4885 |
| US-20010020096-A1 | Process for synthesizing anhydroecgonine derivative | CES2, NPR1, OPRL1 | SLC6A2 185/4885SLC6A4 908/4885SLC6A3 385/4885 |
| US-20020159949-A1 | Methods for diagnosing and monitoring treatment ADHD by assessing the dopamine transporter level | SLC6A3, SLC6A2, SLC18A2 | SLC6A2 2/4885SLC6A4 4/4885SLC6A3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.